“Biosimilar prices should be accepted at 80% of the original prices”

A business conference for the biopharmaceutical drug pricing system opened. While relative issues were focused into 3 items, serious conversations were shared even on the first day, which means it was hard to find agreements.

Under the supervision of Pharmaceutical Benefits Director Hyung-woo Goh of the Ministry of Health and Welfare, the first meeting of the Biopharmaceutical Drug Pricing Sy...